Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response NEW YORK , Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in
